<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The majority of hybridomas we have characterized against Epstein-Barr virions react with the major <z:chebi fb="0" ids="17089">glycoproteins</z:chebi> gp350 and gp220 (gp350/220) </plain></SENT>
<SENT sid="1" pm="."><plain>One of these antibodies, ID4C-1, neutralizes <z:e sem="disease" ids="C0042769" disease_type="Disease or Syndrome" abbrv="">virus infection</z:e> in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>The presence of gp350/220 on the <z:mp ids='MP_0001799'>viral</z:mp> envelope could be confirmed directly by immunoelectron microscopy </plain></SENT>
<SENT sid="3" pm="."><plain>We used lectin affinity (ricin) and immunoaffinity (ID4C-1) to purify gp350/220 and show that this material is able to induce potent virus-neutralizing antibodies </plain></SENT>
<SENT sid="4" pm="."><plain>Absorption of four human and one rabbit anti-Epstein-Barr virus sera with purified gp350/220 suggests that this is the primary component responsible for generating neutralizing antibodies in vivo </plain></SENT>
</text></document>